From the clinic to the capital markets, here is Psychedelic Invest's roundup of the key headlines for the week of July 28 – August 3, 2025.
atai Life Sciences (ATAI): atai shares fall as partner Recognify's schizophrenia cognition trial misses primary endpoint
atai Life Sciences stock slid around 9% in premarket trading after Recognify Life Sciences, an atai-backed company, reported that its Phase 2b trial of inidascamine for cognitive impairment associated with schizophrenia missed its primary endpoint. The setback was a reminder of pipeline risk in atai's broader portfolio even as its lead 5-MeO-DMT program with Beckley Psytech advanced. Investors reacted to the miss as a negative read-through for that non-psychedelic asset.
Source: finance.yahoo.com
Compass Pathways (CMPS): Compass Pathways posts Q2 2025 results and weighs an accelerated COMP360 filing
Compass Pathways reported a Q2 2025 net loss of $38.4 million ($0.41 per share) and ended June with $221.9 million in cash, providing runway into 2027. Following a positive primary-endpoint readout in its first COMP360 psilocybin Phase 3 trial in treatment-resistant depression, management said it was evaluating options for a potentially accelerated regulatory filing. The second pivotal Phase 3 trial continued enrolling, with 26-week data expected in the second half of 2026.
Source: businesswire.com
Mind Medicine (MindMed) (MNMD): MindMed reports Q2 2025 results; three MM120 Phase 3 trials on track
MindMed reported a Q2 2025 net loss of $42.7 million as R&D roughly doubled year-over-year to $29.8 million, reflecting three Phase 3 trials of MM120 ODT (LSD) in generalized anxiety disorder and major depressive disorder. Cash and investments were $237.9 million at June 30, funding operations into 2027 and past the first Phase 3 topline. Voyage topline data was expected in the first half of 2026, with Panorama and Emerge to follow; the company also named Brandi L. Roberts as CFO.
Source: businesswire.com
Psyence Biomedical (PBM): Psyence Biomedical and partner PsyLabs report high-purity, GMP-aligned ibogaine extract
Psyence Biomedical said its strategic partner PsyLabs produced a GMP-aligned ibogaine total-alkaloid extract that met microbial safety standards in third-party testing. The milestone positions the company in the ibogaine supply chain amid rising US policy interest in ibogaine for addiction and veterans' mental health. It gives the small-cap a potential ingredient-supply angle for future clinical and research demand.
Source: globenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.